English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduGlobal celebration of 11 years of discovery and lifesaving innovation in immuno-oncology
Tag: checkpoint blockade
Dual Checkpoint Inhibitor Blockade Shows Promise as First-Line and Salvage Therapy for Merkel Cell Carcinoma Patients
Moffitt Cancer Center is one of two institutions in the U.S. investigating a new dual checkpoint inhibitor therapy with or without stereotactic body radiation therapy for patients with Merkel cell carinoma. Results from the phase 2 clinical trial were published in The Lancet, in conjunction with a presentation at the European Society for Medical Oncology Congress.
Cancer Research Institute Hosts 10th Annual Cancer Immunotherapy Month™ Celebrating Lifesaving Discovery in Immuno-Oncology
Global celebration of 10 years of discovery and lifesaving innovation in immuno-oncology
Updated Report on Trends in Global PD-1/PD-L1 Immunotherapy Clinical Development from the Cancer Research Institute Published in Nature Reviews Drug Discovery
Latest analysis of the global PD-1/PD-L1 immunotherapy clinical development pipeline reveals dramatic growth over past two years in number of trials, drug combinations, and drug targets, but lower patient recruitment rates in the U.S. compared to China.